This novel protection mechanism may be of great importance in improving liposome chemical stability and protecting biological external tissues exposed to the atmosphere, such as skin and eyes, against oxidative damage from endogenous and exogenous sources of ROS, including inflammation and irradiation. The increase in hydration layer of tissues may be achieved by topical applications of these pharmaceutical formulations based on liposomes or emulsions containing lipids such as DHP PEG2000. Keywords: cosmetics, sunscreens

Protects skin and eyes against free radicals and reactive oxygen species

Highlights

• External tissues or surfaces exposed to the atmosphere, such as skin and eyes, undergo oxidative damage.
• The tissues are protected by increasing hydration and introducing a steric barrier to radicals and other oxygen reactive species (ROS) through applying a layer of lipopolymer that binds many water molecules

Our Innovation

• A novel, stable lipopolymer family based on a stable dialkyl phospholipid (DHP-PEG2000) and other dialkyl pegylated liposomes was synthesized and chemically characterized. Provides an extended hydration layer by binding large quantities of non-osmotically active water that acts as a protective barrier for skin and eyes.

Key Features

• Provides liposomes and pegylated lipid which serve as highly effective protection against ionizing g-irradiation and ROS
• Water binding capacity of the novel phospholipid DHP PEG 2000 was found to be 20 times higher than that of conventional phospholipids
• Can be used as protective supplement in skin and eye moisturizers
• Pegylated liposomes are unique in their ablility to reach tumors and inflammation sites
• May replace PEG-DSPE in pegylated liposomes

Development Milestones

• Produce cream and liposome dispersion and micelle dispersion to be tested as protectant against UV and g-irradiation and other types of oxidative damage.
• Comparison with PEG-DSPE

The Opportunity

• Global skin care sales increased 10% in 2005 to top $55 billion
• The anti-aging segment reported the fastest growth with value sales increasing by 13%.

project-id 12-2006-185

Patent granted in DE, ES, FR, UK, IT, US, AU, and IL
(PCT publication no. WO 97/21429)